SCHEMBL6308796

SCHEMBL6308796

Nc1ccn(CCCN2CCCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 2/20 0.39
EHMT1 Q9H9B1 2/20 0.39
HRH3 Q9Y5N1 5/20 0.38
HRH4 Q9H3N8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SIGMAR1 Q99720 2/20 0.38
ALOX15 P16050 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
LTA4H P09960 1/20 0.36
HRH1 P35367 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302511 0.98 HRH3 (0.41) EHMT2EHMT1HRH3HRH4ALDH1A1
SCHEMBL6305135 0.97 ALDH1A1 (0.38) EHMT2EHMT1HRH3HRH4ALDH1A1
SCHEMBL6302885 0.89 ALDH1A1 (0.40) EHMT2EHMT1HRH3ALDH1A1MEN1
SCHEMBL6533138 0.88 ALOX15 (0.41) HRH3ALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL6304851 0.86 ALDH1A1 (0.40) EHMT2EHMT1HRH3ALDH1A1MEN1
SCHEMBL6302848 0.85 KDM1A (0.44) HRH3ALDH1A1KMT2ASIGMAR1
SCHEMBL30786259 0.79 L3MBTL1 (0.41) HRH3HRH4ALDH1A1SIGMAR1L3MBTL1
SCHEMBL6308791 0.76 PARP1 (0.41) HRH3HRH4ALDH1A1L3MBTL1
SCHEMBL18235472 0.76 LMNA (0.42) ALDH1A1MEN1KMT2ASIGMAR1L3MBTL1
SCHEMBL522026 0.76 NR5A2 (0.45) ALDH1A1MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949562-B2 Heterocyclic compounds as ligands of the GABAA receptor NEUROGEN CORPORATION (US) 2005-09-27 US disclosed
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed